Features

Evolving tariff/trade policy, US drug pricing reforms, and a changing global landscape are contributing to an uncertain environment. A DCAT Week education program, featuring experts from IQVIA, will provide in-depth insights on pharma industry performance. 

The wave of US pharmaceutical manufacturing investments has garnered the headlines, but are geographic capacity shifts really in the making? A DCAT Week education program will provide expert analysis, including on the all-important, “make-versus-buy” decision.

What new products, recently or expected to launch in 2026, show blockbuster potential or will be transformative in key therapeutic areas? A look at the companies and products rising to the top of the class. 

The global injectables drugs market is projected for strong growth, driven by demand in biologics and specialty therapeutics. In response, CDMOs/CMOS are expanding production capacity. What are the latest expansions?

As the industry moves further into 2026, what are larger issues impacting industry and company performance? .A view from the C-suite.

A bevy of news on the US drug pricing front: the debut of TrumpRx, a direct-to-patient drug purchasing channel, continued policy moves to most favored drug nation pricing, reforms of PBMs, and the latest in IRA

The wave of US-based manufacturing investments has garnered the headlines, but what are key ex-US capital projects by pharma companies? DCAT Value Chain Insights provides a global roundup. 

The US government released this week the next 15 Rx drugs subject to price negotiations under the Inflation Reduction Act, the landmark legislation that put into place drug pricing reforms…

What are the pressing issues shaping the market for fine chemicals and pharma ingredients in 2026—the challenges and the opportunities? Senior executives from CDMOs share their perspectives.  

The European Parliament has endorsed its position on the Critical Medicines Act, setting the stage to finalize the law to assure security of supply for essential medicines in the EU.